SCYX
SCYNEXIS, Inc.
stockNASDAQ
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.81 | 2026-10-22 | +0.39% | 1.114 |
| 1M | 4.66 | 2026-09-29 | -17.92% | 0.948 |
| 3M | 3.77 | 2026-07-29 | +1.46% | 2.581 |
| 6M | 7.47 | 2026-04-29 | -48.83% | 1.880 |
| 1Y | 5.50 | 2025-10-29 | -30.39% | 1.420 |
| 2Y | 11.20 | 2024-10-29 | -65.85% | — |
| 5Y | 40.08 | 2021-10-29 | -90.46% | 1.274 |
SCYNEXIS, Inc. (NASDAQ:SCYX) stock price today is $3.83, and today's volume is 123,562. SCYX is down 3.165% today. The 30 day average volume is 394,066. SCYX market cap is $38.06M with 9.95M shares outstanding.